|
AstraZeneca PLC on Tuesday said Beyfortus continues to show consistent protection against respiratory syncytial virus in infants. RSV is a contagious virus that causes respiratory illness in infants, including lung infections such as bronchiolitis and pneumonia. The Cambridge, England-based pharmaceutical firm said it will showcase new data across its vaccines and immune therapies RSV portfolio at the ReSViNe conference in Lisbon, Portugal on Wednesday and Thursday. Astra said the data which feature Beyfortus and Synagis will reinforce its commitment to help protect infants from RSV. Beyfortus and Synagis are used to prevent lower respiratory tract disease caused by RSV in newborns. The company said the findings are from the Phase III ’Melody’ clinical trial investigating Beyfortus, also known as nirsevimab, which is a long-acting antibody designed to protect all infants through their first RSV season wit a single dose. Iskra Reic, Astra’s executive vice president for Vaccines & Immune Therapies, said: ‘I am proud of AstraZeneca‘
|
